WE CLAIM:

1. A dry process for the preparation of valganciclovir hydrochloride solid dosage forms wherein the process comprises mixing amorphous valganciclovir hydrochloride with one or more pharmaceutically acceptable excipient(s) and forming into a solid dosage form.
2. The process according to claim 1 wherein the pharmaceutically acceptable excipient is one or more of filler, binder, disintegrant, glidant and lubricant.
3. The process according to claim 1 wherein the process comprises compacting valganciclovir hydrochloride alone or mixed with one or more of pharmaceutically acceptable excipient(s) by roller compactor or slugging; sizing the compacts or slugs into granules by milling; optionally mixing the granules with one or more of pharmaceutically acceptable excipients and forming a solid dosage form.
4. The process according to claim 3 wherein the compaction is done by roller compactor.
5. The process according to claims 3 wherein the solid dosage form is a tablet.
6. The process according to claim 3 wherein the solid dosage form is a capsule.
7. The process according to claim 1 wherein the mixture is directly compressed into a tablet.
8. The process according to claim 2 wherein the filler is one or more of microcrystalline cellulose, mannitol, sucrose, lactose, dextrose, calcium carbonate and sorbitol.
9. The process according to claim 2 wherein the binder is one or more of polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, starch and starch based binders, gelatin and gums.
10. The process according to claim 2 wherein the disintegrant is one or more of crospovidone, croscarmellose sodium, starch, hydroxypropylcellulose, hydroxypropylmethylcellulose, gums and sodium starch glycolate.
11. The process according to claim 2 wherein the glidant is one or more of talc and colloidal silicon dioxide.
12. The process according to claim 2 wherein the lubricant is one or more of magnesium stearate, stearic acid and sodium stearyl fumarate.

13. A solid dosage form comprising amorphous valganciclovir hydrochloride, filler, disintegrant, binder and lubricant prepared by the process of claim 1.

14. A solid dosage form comprising amorphous valganciclovir hydrochloride, microcrystalline cellulose, cross-linked polyvinylpyrrolidone, polyvinylpyrrolidone and magnesium stearate prepared by the process of claim 2.

15. The solid dosage form according to claim 13 wherein the solid dosage form is a tablet.

16. The solid dosage form according to claim 13 wherein the solid dosage form is a capsule.

17. A solid dosage form according to claim 13 wherein it additionally comprises another drug in a therapeutically effective amount.

18. A method of administering amorphous valganciclovir hydrochloride to a patient in need thereof as a solid dosage form prepared by a dry process wherein the process comprises mixing amorphous valganciclovir hydrochloride with one or more of pharmaceutically acceptable excipient(s) and forming into a solid dosage form.